Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04477395
Other study ID # RNN/251/17/KE
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 1, 2017
Est. completion date September 30, 2021

Study information

Verified date October 2022
Source Medical University of Lodz
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Periodontitis is a chronic multifactorial inflammatory disease that lead to the loss of supportive tissues around the teeth with gradual deterioration of masticatory function and esthetics, resulting eventually in the decrease of the quality of life. Host immune response triggered by bacterial biofilm is responsible for the chronic periodontal inflammation and ongoing tissue loss. Polyunsaturated fatty acids (PUFAs) omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have anti-inflammatory properties, thus may be used for the treatment of chronic inflammatory diseases. This study is aimed to evaluate the effect of dietary supplementation with PUFAs omega-3 in the patients with periodontitis stage III and IV.


Description:

Periodontitis is highly prevalent oral disease in humans affecting nearly 50% of the population worldwide. Periodontitis is multifactorial disease individually accelerated or decelerated by different factors. One of them, a bacterial biofilm, leads to dysbiosis and raise of Gram-negative bacteria.This results in the activations of immune response and clinical signs of periodontal tissue inflammation. Host modulation therapy seems to be an adequate concept for the treatment of periodontal diseases. The main assumption of this therapy is to reduce by-stander tissue destruction, to ensure rapid resolution of inflammation or even to promote regeneration of the periodontal tissues by modifying or down-regulating the destructive aspects of the host response and by up-regulating the protective or regenerative responses The goal of the present study was to assess the effect of high-dose omega-3 PUFAs EPA and DHA on the clinical outcome of non-surgical treatment of the patients with generalized periodontitis stage III and IV. It was presumed that dietary supplementation with high-dose EPA and DHA would have the potential to induce a measurable clinical outcome as a result of reduction of inflammation and minimizing tissue damage mediated by anti-inflammatory effect of omega-3 PUFAs. To address this issue, a randomized clinical trial was designed in which EPA and DHA were supplemented in adjunction to the standard periodontal therapy, scaling and root planning (SRP). Clinical outcomes of active versus control therapies were measured in addition to the quantifications of saliva cytokines, chemokines, subgingival biofilm composition and serum levels of lipids.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date September 30, 2021
Est. primary completion date April 10, 2021
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - at least 18 scorable teeth (not including third molars), - =4 teeth with PD =6 mm, CAL =5 mm, - radiographic evidence of bone loss more than one-third of the root length, - no periodontal treatment performed within last 6 months. Exclusion Criteria: - smoking, - diabetes, - any diseases or disorders that compromise wound healing, - chronic inflammatory disease, history of radio- or chemotherapy, - nonsteroidal anti-inflammatory drug (NSAIDs) intake > 3 days, - use of antibiotics or corticosteroids 3 months prior to the study.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
fish oil
SRP will be supplemented with the dietary fish oil rich in omega-3 PUFAs EPA and DHA for 6 months. Fish oil (BioMarine Medical, 200 ml liquid), obtained from Tasmanian deep sea shark and Norwegian cod liver and sardine, anchovy and mackerel muscle, will be administered two times a day at a dose 10 ml. Daily dose of 20 ml provides 2.6 g of EPA and 1.8 g of DHA.
Procedure:
SRP only
Scaling and root planing will be the only method of treatment.

Locations

Country Name City State
Poland Department of Periodontology and Oral Mucosal Diseases Lodz

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Lodz

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the percent of closed pockets The percent of closed pockets (PD = 4 mm and BOP-) at 3 and 6 months in relation to baseline 3 and 6 months
Secondary Change in the probing depth (PD) Mean values of probing depth of all sites with initial PD = 4 mm 3 and 6 months
Secondary Change in the clinical attachment level (CAL) Mean values of clinical attachment level of all sites with initial PD = 4 mm 3 and 6 months
Secondary Change in the bleeding on probing (BOP) Percent of all sites with bleeding on probing 3 and 6 months
Secondary Change in the number of sites with PD = 4 mm and BOP+ Mean values of number of sites with PD = 4 mm and BOP+ 3 and 6 months
See also
  Status Clinical Trial Phase
Completed NCT04712630 - Non-Incised Papillae Surgical Approach (NIPSA) With and Without Graft N/A
Completed NCT06127069 - Treatment of Residual Pockets in Periodontal Patients Using an Oscillating Chitosan Device N/A
Completed NCT04964167 - Indocyanine-green Mediated Photosensitizer VS Aloe Vera Gel: Adjunct Therapy to Scaling and Root Planing in Patients With Chronic Periodontitis Phase 4
Completed NCT05906797 - Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis. N/A
Recruiting NCT03997552 - NIPSA Versus Marginal Approach by Palatal Incision and MIST in Periodontal Regeneration N/A
Completed NCT05530252 - Effects of AMP Application After Non-surgical Periodontal Therapy on Treatment of Periodontitis Phase 4
Completed NCT04881357 - Antiplaque/Antigingivitis Effect of Lacer Oros Integral N/A
Recruiting NCT03790605 - A Clinical Trial to Study the Effect of a Drug, Curcumin in Patients With Periodontitis Phase 3
Enrolling by invitation NCT04971174 - Outcomes of Periodontal Regenerative Treatment
Not yet recruiting NCT05568290 - Interleukin-38 Levels in Individuals With Periodontitis
Completed NCT04383561 - Relationship Between LRG and Periodontal Disease N/A
Recruiting NCT03997578 - Non-incised Papillae Surgical Approach (NIPSA) and Connective Tissue Graft Plus Emdogain for Periodontal Defects N/A
Completed NCT03901066 - Smoking Dependence and Periodontitis
Enrolling by invitation NCT04956211 - Periodontal Treatment and Ischemic Stroke N/A
Recruiting NCT05971706 - Ozone Application in Periodontal Treatment N/A
Recruiting NCT06099574 - A Study on the Oral Health Status of Pregnant Women With Gestational Diabetes and Its Correlation With Oral Flora
Completed NCT04402996 - Meteorin-like Levels in Individuals With Periodontitis
Active, not recruiting NCT05311657 - Oral Health and Severe COPD
Not yet recruiting NCT06453278 - (DDS) in India: a Screening Tool to Identify Prediabetes and Undiagnosed Type 2 Diabetes in Dental Settings
Not yet recruiting NCT05643287 - The Effect of Time on the Outcome of Periodontal Treatment. N/A